Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title> <jats:p>Spontaneous binding of infected erythrocytes to uninfected erythrocytes to form rosettes is a property of some strains of <jats:italic>Plasmodium falciparum</jats:italic> that is linked to severe complications of malaria. Curdlan sulfate (CRDS) is a sulfated glycoconjugate compound that is chemically similar to known rosette-inhibiting drugs such as heparin. CRDS has previously been shown to have antimalarial activity in vitro and is safe for clinical use. Here we show that CRDS at therapeutic levels (10 to 100 μg/ml) significantly reduces rosette formation in vitro in seven <jats:italic>P. falciparum</jats:italic> laboratory strains and in a group of 18 African clinical isolates. The strong ability to inhibit rosetting suggests that CRDS has the potential to reduce the severe complications and mortality rates from <jats:italic>P. falciparum</jats:italic> malaria among African children. Our data support further clinical trials of CRDS.</jats:p>

Original publication

DOI

10.1128/aac.01216-06

Type

Journal article

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

04/2007

Volume

51

Pages

1321 - 1326